UTAH MEDICAL PRODUCTS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $38.5M | $40.9M | $50.2M | $52.3M | $49.1M |
| Cost of revenue | $16.5M | $16.8M | $20.2M | $20.1M | $18.1M |
| Gross profit | $22.0M | $24.1M | $30.0M | $32.2M | $30.9M |
| Research and development | $668,000 | $813,000 | $560,000 | $493,000 | $526,000 |
| Operating income | $11.4M | $13.6M | $16.8M | $19.8M | $18.9M |
| Pretax income | $14.1M | $16.8M | $20.1M | $20.7M | $19.1M |
| Income tax expense | $2.8M | $2.9M | $3.5M | $4.2M | $4.3M |
| Net income | $11.3M | $13.9M | $16.6M | $16.5M | $14.8M |
| Balance Sheet | |||||
| Cash and equivalents | $85.8M | $83.0M | $92.9M | $75.1M | $61.0M |
| Current assets | $97.7M | $96.3M | $106.3M | $89.9M | $73.2M |
| Total assets | $122.5M | $122.5M | $135.5M | $123.9M | $115.6M |
| Current liabilities | $2.6M | $3.8M | $4.7M | $6.0M | $3.7M |
| Total liabilities | $3.3M | $5.1M | $7.1M | $9.6M | $8.5M |
| Stockholders' equity | $119.3M | $117.4M | $128.3M | $114.3M | $107.1M |
| Cash Flow Statement | |||||
| Cash from operations | $14.7M | $14.8M | $22.3M | $21.1M | $21.2M |
| Depreciation and amortization | $826,000 | $730,000 | $623,000 | $612,000 | $636,000 |
| Stock-based compensation | $373,000 | $256,000 | $225,000 | $183,000 | $166,000 |
| Capital expenditure | $371,000 | $230,000 | $639,000 | $809,000 | $552,000 |
| Free cash flow | $14.3M | $14.6M | $21.6M | $20.3M | $20.7M |
| Dividends paid | $4.0M | $4.3M | $4.3M | $3.2M | $11.5M |
| Share repurchases | $8.4M | $20.0M | $0 | $2.5M | $0 |
| Impairments | — | — | $0 | $0 | $0 |
Shares outstanding 3.2M · Free float 92.0%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.